Citicoline for Alcohol Dependence

The University of Texas System (UT)

Status and phase: Completed; Phase 4

Conditions: Alcohol Dependence

Treatments: Drug: Citicoline; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02074735

072012-088

Details and patient eligibility

About

The purpose of this study is to determine if citicoline, as an add-on therapy, will help reduce alcohol use in outpatients with alcohol dependence.

Full description

A total of 62 outpatients with alcohol dependence will be enrolled in a 12-week, randomized, placebo-controlled trial. Participants will be randomized to receive either placebo or citicoline.

Throughout the study, participants will be asked about their alcohol use and any withdrawal or craving symptoms. Depressive symptoms will be measured as well. Cognition and memory will be measured as well with a neurocognitive battery. Blood will be drawn at study start and week 12 to measure liver enzyme levels.

Appointments will be weekly for the entire study. Participants will have a physician follow-up at every study appointment.

Enrollment: 62 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women age 18-75 years old with diagnosis of alcohol dependence
• Average alcohol use of at least 28 drinks per week and at least 7 heavy drinking days (defined as 4 or more drinks/day for women, 5 or more drinks/day for men) in the past 28 days
• No alcohol use within 72 hours of randomization (maximum abstinence 7 days)
• CIWA-Ar (withdrawal scale) score less than or equal to 8 at randomization (consistent with minimal or no withdrawal symptoms and medication probably not needed)

Exclusion criteria

• Vulnerable populations including individuals with intellectual disability or dementia, prison or jail inmates, pregnant or nursing women, or women of childbearing age who will not use acceptable forms of birth control
• History of arrhythmias
• Myocardial infarction or coronary artery bypass graft surgery in the past 6 months
• Active angina or blood pressure >170/105
• High risk for suicide (defined as suicide attempt in past 6 months, or current suicidal ideation with plan and intent)
• High risk of violence toward others (defined as assault in past 6 months, or violent thoughts with evidence of plan and intent)
• Intensive outpatient treatment for substance abuse (AA, NA meetings or weekly therapy/counseling for substance use for at least 28 days prior to randomization will be allowed)
• Dependence (not just abuse) on substances other than alcohol or nicotine
• History of delirium tremens or other sever alcohol withdrawal symptoms, history of cirrhosis or AST or ALT >3 times normal, or other unstable medical condition (e.g. uncontrolled diabetes)
• History of bipolar disorder or schizophrenia
• Current major depressive episode (past episodes and current milder depressive symptoms allowed) or other psychiatric disorder that should be a major focus of treatment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

62 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Placebo schedule will mimic the schedule of the active comparator citicoline. Placebo will be started at the randomization visit (week 0, mimicking 500 mg/day of citicoline), then increased at week 2 to mimic 1000 mg/day citicoline, then increased to mimic 1500 mg/day of citicoline at week 4, and then increased to mimic 2000 mg/day of citicoline at week 6 until the end of week 12.

Treatment:

Drug: Placebo

Citicoline

Active Comparator group

Description:

Citicoline will be started at 500 mg/day at the randomization visit (week 0), then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and then 2000 mg/day at week 6 until the end of week 12.

Treatment:

Drug: Citicoline